Back on June 3, when Pfizer and Lilly both signed China deals on the same day, we wrote that the political rhetoric said decouple while the deal flow said accelerate, and that the two could not run in opposite directions forever. This week the gap started to close.
The House Select Committee on China sent letters to the CEOs of Merck, AbbVie, Lilly, Pfizer, and Bristol Myers Squibb demanding details on the hundreds of clinical trials they run in China. The focus: sites in the Xinjiang region and at hospitals tied to the Chinese military. All five have until July 17 to respond. Nobody is accused of breaking the law. But the framing is unmistakable. Chairman John Moolenaar called China the cheapest and fastest place in the world to run early trials and questioned whether that speed is exposing American IP and aiding China’s military biotech ambitions.
The numbers the committee cited are specific. Merck has run 224 studies in China since 2005, including 40 at military tied sites. Pfizer has run at least 43 at military medical centers. The industry spent $138 billion licensing Chinese drugs in 2025. Now Washington wants a say in how those trials are run.
Separately, BridgeBio landed $1 billion in preferred equity from Sixth Street and KKR. Orca Bio priced its new cell therapy at $428,000. The FDA expanded Casgevy into younger children through the CNPV program. And Nature retracted a widely cited lung cancer study—the second pivotal retraction in two days.
The House China Probe: What It Means and What It Does Not
What Happened: Chairman John Moolenaar sent letters to Merck and AbbVie on June 29, then to Lilly, Pfizer, and BMS within days, opening a national security investigation into how the five largest U.S. pharmaceutical companies manage their clinical trials in China.
What the Committee Is Asking
The committee wants details on due diligence, data protection, and IP safeguards at Chinese trial sites, with specific attention to two categories: sites in the Xinjiang region, where the Chinese government’s treatment of the Uyghur population has drawn international condemnation, and hospitals affiliated with China’s People’s Liberation Army, where the military connection raises questions about whether trial data or technology could be accessed by China’s defense establishment.
The committee is not accusing anyone of doing anything wrong. Merck said patient safety and ethical integrity remain central to its research. The Chinese embassy dismissed the probe as having “nothing credible” in it. But the letters are detailed and specific. The committee knows exactly how many studies each company has run in China and exactly which sites have military affiliations. This is not a fishing expedition. It is a targeted inquiry with a clear deadline.
Why This Matters More Than a Typical Washington Letter
This probe arrives alongside the Biotech Investment National Security Act, which would put U.S. licensing deals with Chinese firms under Treasury review and which explicitly names the Pfizer and BMS China deals as the kind of transaction it wants to stop. For the past six months, the smart money has treated the COINS Act and its successors as political noise that would never catch up to the deal flow. That assumption is now being tested.
The industry spent $138 billion licensing Chinese drugs in 2025. In 2026, the China pipeline accelerated further: BMS/Hengrui ($15.2 billion, 13 programs), Pfizer/Innovent ($10.5 billion, 12 programs), Lilly/Haisco ($3 billion plus, five programs), Lilly/Abbisko (undisclosed), GSK/SiranBio ($1 billion), AbbVie/Haisco (Nav1.8), Merck/Kelun Biotech (sac TMT). The clinical data from these partnerships have been extraordinary. Merck’s sac TMT cut progression risk by 65% in lung cancer. Akeso’s ivonescimab became the first Chinese drug in the ASCO plenary in 61 years. Hengrui presented 90 plus studies at ASCO.
The deals already signed are safe. Nothing in the committee’s letters or the pending legislation unwinds an existing agreement. The risk is entirely forward looking. It falls on the next wave of licensing deals and on trials still being placed in China. If you are evaluating a Chinese asset right now, the conversation just changed. “It is cheaper and faster” is exactly the rationale the committee is attacking. The clinical and economic case for China sourcing has not weakened. But the political risk of making that case has increased, and it is not coming back down before the midterms.
The market mostly shrugged. Lilly slipped 2.5% and AbbVie eased about 1% on the news, then both largely stabilized. That tells you investors see this as a slow building overhang, not an immediate threat. That read is probably right for now. But the direction of travel is clear.
Our Pro brief lays out which deals are safe, which are exposed, and what the July 17 deadline means for forward looking China strategy. [Details below.]
BridgeBio Raises $1B Without Selling a Single Share
What Happened: BridgeBio secured $1 billion in preferred equity from Sixth Street Partners and KKR, one of the largest non dilutive financings of the year.
Why This Deal Structure Matters
Non dilutive means BridgeBio did not issue new common shares to raise the money. Existing shareholders keep their ownership stakes intact. The capital comes in as preferred equity, which sits above common stock in the capital structure but does not flood the share count the way a traditional equity offering would.
This structure works because BridgeBio has a real commercial asset to underwrite against: Attruby in ATTR cardiomyopathy, which showed a survival signal versus Pfizer’s tafamidis and is building a commercial franchise. Sixth Street and KKR are not betting on preclinical science. They are investing against visible revenue with downside protection through the preferred equity structure.
The raise gives BridgeBio deep capital to push its rare disease and cardiology franchises through late stage development and potential launches without going back to the equity market. Combined with the BBP 418 Priority Review for limb girdle muscular dystrophy (potentially the first approved treatment for any form of LGMD), BridgeBio is building toward a multi franchise company with the capital to get there.
The financing environment for companies with commercial or near commercial assets is genuinely strong right now. Forty private biotechs disclosed rounds of $100 million or more in the first half of 2026. Definium raised $805 million within 48 hours of a Phase 3 win. BridgeBio raised $1 billion without dilution. The capital is there for companies that have de risked their lead asset. That is the dividing line in this market: proven science attracts creative, founder friendly capital at speed. Earlier stage names face harder choices.
Orca Bio Prices Tregzi at $428,000
What Happened: Orca Bio set a $428,000 list price for Tregzi, a regulatory T cell therapy for blood cancer patients undergoing stem cell transplant.
Why This Matters: The pricing lands Tregzi in the same broad range as other one time cell therapies and reflects the manufacturing complexity of engineered T cell products. Tregzi is designed to reduce transplant complications like graft versus host disease, a condition where the transplanted immune cells attack the patient’s own tissues. GVHD is a major cause of morbidity and mortality after stem cell transplant, and a therapy that meaningfully reduces it would justify its price on total cost of care grounds—because the alternative is months of hospitalization, intensive immunosuppression, and the organ damage that GVHD causes.
The launch adds another tool to the growing cell therapy armamentarium. Yescarta, Carvykti, Abecma, and now Tregzi. The field is steadily moving from novelty to standard of care, and the pricing is settling into a range that payers, while not enthusiastic about, are learning to accommodate for products that demonstrate durable clinical value.
Casgevy Reaches Younger Children Through the CNPV Program
What Happened: The FDA expanded Vertex and CRISPR’s Casgevy into a younger pediatric population for sickle cell disease, broadening it beyond the 12 and older group it was first cleared for. The expansion came through the CNPV program.
Why This Matters: Casgevy is the first CRISPR based medicine on the market. Reaching younger patients matters because earlier intervention can prevent the irreversible organ damage that sickle cell disease causes over time. The disease attacks red blood cells starting in infancy, and the cumulative damage to the spleen, kidneys, brain, and lungs worsens with each passing year. A gene therapy that corrects the underlying genetic defect before that organ damage accumulates has the potential to fundamentally change the disease trajectory for a child.
The CNPV pathway is notable. Whatever the program’s transparency issues (three undisclosed recipients still unresolved), it continues to pull meaningful approvals forward. Foundayo in 50 days. Otarmeni for hearing loss. And now Casgevy for younger sickle cell patients. The program’s practical impact on getting important therapies to patients faster is real, even if its governance needs work.
The pediatric expansion also matters for the gene therapy field broadly. Casgevy’s approval trajectory—first in older patients, then expanded into younger populations—is the same pattern that has defined successful gene therapy launches across other diseases. Zolgensma in SMA started in infants and expanded. Elevidys in Duchenne started in specific age groups and broadened. Each expansion demonstrates that the therapy works across a wider population, builds physician confidence, and increases the addressable patient base. For Vertex and CRISPR, reaching younger sickle cell patients is both a clinical milestone (earlier treatment, better outcomes) and a commercial one (more patients eligible, longer lifetime benefit from a one time therapy).
Two Pivotal Retractions in Two Days
What Happened: Nature retracted a widely cited study that linked lung cancer survival to the timing of PD 1 treatment. Coming one day after a top journal retracted the pivotal study behind Amgen’s Tavneos, it is the second pivotal retraction in two days.
Why This Pattern Matters
One retraction is a single paper. Two in two days, both involving widely cited studies that influence clinical practice or regulatory decisions, is a pattern worth paying attention to.
The Tavneos retraction undercut the evidence base that regulators used to approve a marketed drug, compounding an already devastating sequence of FDA scrutiny, voluntary withdrawal request, and European revocation recommendation. The lung cancer PD 1 study retraction is different in kind—it involves a research finding about treatment timing rather than a pivotal drug approval trial—but the effect on clinical confidence is similar. Physicians and drug developers who relied on that study to guide treatment decisions now have to reconsider those decisions.
The lesson of this week is that peer review is not the final word. The published literature is getting a harder second look through post publication analysis, data audits, and integrity investigations that were less common even five years ago. For anyone relying on published studies to guide strategy, prescribing, or investment decisions, the takeaway is straightforward: treat the evidence base as a living document that can change, not as settled fact. The data that justified an approval or informed a treatment guideline this year may not be standing next year.
Strategic Themes
1. The China Pipeline Just Got a Political Price Tag
The deal flow has not stopped. The clinical data are still compelling. But the cost of doing business with Chinese biotech just went up by a factor that cannot be modeled on a spreadsheet. The House Select Committee has names, numbers, and a deadline. The Biotech Investment National Security Act is moving through Congress. The assumption that China sourcing would remain frictionless no longer holds. Companies evaluating Chinese assets need to add political and reputational risk to the clinical and financial calculus they already perform. The $138 billion that flowed in 2025 was underwritten on an assumption of easy access. That assumption is eroding.
2. Non Dilutive Capital at Scale Is Available for Companies That Have De Risked
BridgeBio at $1 billion. Apogee at $1.3 billion from Blackstone (before AbbVie acquired it). Definium at $805 million. The financing environment rewards proven assets with creative structures that preserve shareholder value. The message for biotech CEOs: if you have a commercial or late stage product generating real evidence of value, the capital is there without selling equity at a discount. If you do not have that evidence yet, the path is harder.
3. Cell Therapy Pricing Is Finding Its Band
Tregzi at $428,000 joins Casgevy (over $2 million for gene therapy in sickle cell), Yescarta, and Carvykti in a pricing landscape where the market is learning to accommodate six figure cell therapy prices for products that demonstrate clear clinical value and replace expensive downstream complications. The band is forming. Future cell therapy launches will price against this emerging benchmark.
4. Two Retractions in Two Days Says the Evidence Base Is Under New Scrutiny
Tavneos pivotal study retracted. Nature lung cancer PD 1 study retracted. The post publication integrity environment is getting tougher. For pharma companies, the lesson is to ensure that their own pivotal data are bulletproof, because the scrutiny that used to come only from regulators now also comes from journals, independent analysts, and the scientific community at large. For investors, the lesson is that approval does not settle the evidence question permanently.
Frequently Asked Questions
What is the House China probe?
The House Select Committee on China opened an investigation into the China clinical trials of Merck, AbbVie, Lilly, Pfizer, and BMS. All five have until July 17 to respond with details on data protection, ethics, and oversight at sites in Xinjiang and at Chinese military hospitals. No wrongdoing is alleged.
How many China trials are involved?
Merck has run 224 studies in China since 2005, including 40 at military tied sites. Pfizer has run at least 43 at military medical centers. The committee cited $138 billion in Chinese drug licensing in 2025.
What is the BridgeBio raise?
$1 billion in preferred equity from Sixth Street Partners and KKR. Non dilutive, meaning no new common shares issued. The capital supports BridgeBio’s rare disease and cardiology pipeline including Attruby in ATTR cardiomyopathy.
What is Tregzi?
Orca Bio’s regulatory T cell therapy for blood cancer patients undergoing stem cell transplant. $428,000 list price. Designed to reduce transplant complications like graft versus host disease.
What happened with Casgevy?
The FDA expanded the sickle cell gene therapy into younger children through the CNPV program. Casgevy is the first CRISPR based medicine on the market. Earlier treatment can prevent the irreversible organ damage sickle cell causes over time.
What are the two retractions?
A top journal retracted the pivotal Tavneos study (Wednesday). Nature retracted a lung cancer PD 1 treatment timing study (Thursday). Two pivotal retractions in two days from different journals, both affecting clinical practice or regulatory decisions.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The China Pipeline’s Political Price Tag. We lay out which existing deals are safe, which companies face the most exposure based on trial site geography, and what business development teams should do before the July 17 deadline. The deals already signed are not at risk. The next ones now carry political cost that has to be priced in.
Cell Therapy Pricing. We analyze where Tregzi’s $428,000 fits in the emerging pricing band for engineered cell therapies, what it signals about the next wave of launches, and how payers are evaluating these products on total cost of care rather than sticker price.
A Billion Dollars, No Dilution. We assess why BridgeBio’s preferred equity structure is the financing model more commercial stage biotechs will copy, where the dividing line sits between companies that can access non dilutive capital and those that cannot, and what Sixth Street and KKR see in the Attruby franchise.
Plus: Casgevy pediatric expansion through CNPV, research integrity trends after two retractions, Revolution filing watch, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
